Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran, Iran.
National Center for Health Insurance Research, Tehran, Iran.
BMJ Open. 2022 Dec 13;12(12):e067573. doi: 10.1136/bmjopen-2022-067573.
Stroke is the second most prevalent cardiovascular disease in Iran. This study investigates the estimation and predictors of hospitalisation expenses and in-hospital mortality for patients who had a stroke in Iranian hospitals.
Patients who had a stroke in Iran between 2019 and 2020 were identified through the data collected from the Iran Health Insurance Organization and the Ministry of Health and Medical Education. This study is the first to conduct a pervasive, nationwide investigation.
This is a cross-sectional, prevalence-based study. Generalised linear models and a multiple logistic regression model were used to determine the predictors of hospitalisation expenses and in-hospital mortality for patients who had a stroke.
A total of 19 150 patients suffering from stroke were studied.
Mean hospitalisation expenses per patient who had a stroke in Iran amounted to US$590.91±974.44 (mean±SD). Mean daily hospitalisation expenses per patient who had a stroke were US$55.18±37.89. The in-hospital mortality for patients who had a stroke was 18.80%. Younger people (aged ≤49 years) had significantly higher expenses than older patients. The OR of in-hospital mortality in haemorrhagic stroke was significantly higher by 1.539 times (95% CI, 1.401 to 1.691) compared with ischaemic and unspecified strokes. Compared with patients covered by the rural fund, patients covered by Iranian health insurance had significantly higher costs by 1.14 times (95% CI, 1.186 to 1.097) and 1.319 times (95% CI, 1.099 to 1.582) higher mortality. There were also significant geographical variations in patients who had a stroke's expenses and mortality rates.
Applying cost-effective stroke prevention strategies among the younger population (≤49 years old) is strongly recommended. Migration to universal health insurance can effectively reduce the inequality gap among all insured patients.
中风是伊朗第二大常见心血管疾病。本研究旨在调查伊朗医院中风患者住院费用和住院死亡率的估计值和预测因素。
通过从伊朗健康保险组织和卫生部收集的数据,确定了 2019 年至 2020 年期间在伊朗发生中风的患者。这是首次进行全面、全国性调查。
这是一项横断面、基于患病率的研究。使用广义线性模型和多逻辑回归模型来确定中风患者住院费用和住院死亡率的预测因素。
共研究了 19150 名中风患者。
伊朗中风患者的平均住院费用为 590.91 美元±974.44 美元(平均值±标准差)。中风患者的平均日住院费用为 55.18 美元±37.89 美元。中风患者的住院死亡率为 18.80%。年龄≤49 岁的年轻人的费用明显高于年龄较大的患者。与缺血性和未特指性中风相比,出血性中风患者的住院死亡率的 OR 显著增加 1.539 倍(95%置信区间,1.401 至 1.691)。与农村基金覆盖的患者相比,伊朗健康保险覆盖的患者的费用显著增加 1.14 倍(95%置信区间,1.186 至 1.097)和 1.319 倍(95%置信区间,1.099 至 1.582),死亡率更高。中风患者的费用和死亡率也存在显著的地域差异。
强烈建议在年轻人群(≤49 岁)中实施具有成本效益的中风预防策略。向全民健康保险的转变可以有效缩小所有参保患者之间的不平等差距。